ERBB2 and breast cancer: Statistically significant differences in overall survival distributions of HR+/Her2+ (188 cases), HR+/Her2− (1404 cases), HR−/Her2+ (117 cases), and triple-negative (182 cases) breast cancer were observed (p = 0.003) (Figure 7, Table 8).